Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ascorbate and Ferumoxytol with Temozolomide and Radiation for Newly Diagnosed Glioblastoma
NCT04900792Phase 1Active, not recruiting
- Start
- Feb 2023
- Primary completion
- May 2025
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ferumoxytol and ascorbic acid in glioblastoma (GBM) (2 cohorts). Primary endpoint: Dose Limiting Toxicities. Started Feb 2023; status: active, not recruiting.
02
Drugs
ferumoxytolascorbic acid
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04900792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04900792.